Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572

被引：0
|
作者：
Schiff, David [1 ]
Sarkaria, Jann [2 ]
Decker, Paul [2 ]
Buckner, Jan [2 ]
Galanis, Evanthia [2 ]
Dancey, Janet [3 ]
Giannini, Caterina [2 ]
Brown, Paul [2 ]
Wiesenfeld, Martin [4 ]
Jaeckle, Kurt [5 ]
机构：
[1] Univ Virginia, Hlth Sci Ctr, Charlottesville, VA USA
[2] Mayo Clin, Rochester, MN USA
[3] Natl Canc Inst, Bethesda, MD USA
[4] Cedar Rapids Oncol Project, Cedar Rapids, IA USA
[5] Mayo Clin, Jacksonville, FL 32224 USA
来源：
NEURO-ONCOLOGY | 2007年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：518 / 518
页数：1
相关论文
共 50 条
  • [1] FEASIBILITY/TOLERABILITY RESULTS FROM A PHASE I/II STUDY OF TEMSIROLIMUS (CCI-779) AND SORAFENIB IN RECURRENT GLIOBLASTOMA: NORTH CENTRAL CANCER TREATMENT GROUP (NCCTG) N0572
    Schiff, David
    Sarkaria, Jann
    Decker, Paul
    Buckner, Jan
    Galanis, Evanthia
    Dancey, Janet
    Giannini, Caterina
    Brown, Paul
    Wiesenfeld, Martin
    Jaeckle, Kurt
    NEURO-ONCOLOGY, 2009, 11 (02) : 232 - 232
  • [2] NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study.
    Jaeckle, K. A.
    Schiff, D.
    Anderson, S. K.
    Galanis, E.
    Stella, P. J.
    Flynn, P. J.
    Sarkaria, J. N.
    Scheithauer, B. W.
    Erickson, B. J.
    Buckner, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
    Galanis, E
    Buckner, JC
    Maurer, MJ
    Kreisberg, JL
    Ballman, K
    Boni, J
    Peralba, JM
    Jenkins, RB
    Dakhil, SR
    Morton, RF
    Jaeckle, KA
    Scheithauer, BW
    Dancey, J
    Hidalgo, M
    Walsh, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5294 - 5304
  • [4] Phase 1/2 Trial of Temsirolimus and Sorafenib in the Treatment of Patients With Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
    Schiff, David
    Jaeckle, Kurt A.
    Anderson, S. Keith
    Galanis, Evanthia
    Giannini, Caterina
    Buckner, Jan C.
    Stella, Phillip
    Flynn, Patrick J.
    Erickson, Bradley J.
    Schwerkoske, John F.
    Kaluza, Vesna
    Twohy, Erin
    Dancey, Janet
    Wright, John
    Sarkaria, Jann N.
    CANCER, 2018, 124 (07) : 1455 - 1463
  • [5] NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM).
    Galanis, E
    Buckner, JC
    Maurer, M
    Ballman, K
    Hidalgo, M
    Kreisberg, JI
    Boni, J
    James, CDD
    Jenkins, RB
    Walsh, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 107S - 107S
  • [6] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Chang, SM
    Wen, P
    Cloughesy, T
    Greenberg, H
    Schiff, D
    Conrad, C
    Fink, K
    Robins, HI
    De Angelis, L
    Raizer, J
    Hess, K
    Aldape, K
    Lamborn, KR
    Kuhn, J
    Dancey, J
    Prados, MD
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) : 357 - 361
  • [7] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Susan M. Chang
    Patrick Wen
    Timothy Cloughesy
    Harry Greenberg
    David Schiff
    Charles Conrad
    Karen Fink
    H. Ian Robins
    Lisa De Angelis
    Jeffrey Raizer
    Kenneth Hess
    Ken Aldape
    Kathleen R. Lamborn
    John Kuhn
    Janet Dancey
    Michael D. Prados
    Investigational New Drugs, 2005, 23 : 357 - 361
  • [8] A Phase II study of Temsirolimus (CCI-779) in patients with metastatic and/or recurrent endometrial cancer - NCICCTG IND 160
    Oza, A. M.
    Elit, L.
    Biagi, J.
    Panasci, L.
    Tonkin, K.
    Tsao, M.
    Dore, N.
    Dancey, J.
    Eisenhauer, E.
    Seymour, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 261 - 261
  • [9] NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi)
    Jaeckle, Kurt A.
    Schiff, David
    Anderson, S. Keith
    Galanis, Evanthia
    Stella, Philip J.
    Flynn, Patrick J.
    Sarkaria, Jann Nagina
    Giannini, Caterina
    Erickson, Bradley J.
    Buckner, Jan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients
    Sarkaria, J. N.
    Galanis, E.
    Wu, W.
    Giannini, C.
    Jaeckle, K. A.
    Doyle, L.
    Uhm, J.
    Brown, P.
    Dietz, A. B.
    Buckner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345